Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1279865 | 1.00 | TACR1 (0.44) | TACR1GPR119MMP13USP30JAK2 | |
| SCHEMBL16380488 | 1.00 | TACR1 (0.44) | TACR1GPR119MMP13USP30JAK2 | |
| SCHEMBL1280205 | 1.00 | TACR1 (0.44) | TACR1GPR119MMP13USP30JAK2 | |
| SCHEMBL1279861 | 1.00 | TACR1 (0.44) | TACR1GPR119MMP13USP30JAK2 | |
| SCHEMBL12468333 | 0.90 | PPARG (0.39) | SCN9ASLC6A9 | |
| SCHEMBL14837995 | 0.85 | MMP13 (0.43) | TACR1GPR119MMP13TGFBR1MAPT | |
| SCHEMBL1689415 | 0.85 | MMP13 (0.43) | TACR1GPR119MMP13TGFBR1MAPT | |
| SCHEMBL9108211 | 0.85 | MMP13 (0.45) | TACR1GPR119MMP13TGFBR1MAPT | |
| SCHEMBL9108220 | 0.85 | MMP13 (0.45) | TACR1GPR119MMP13TGFBR1MAPT | |
| SCHEMBL9110045 | 0.84 | DPP4 (0.45) | TACR1GPR119MMP13TGFBR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000191-B2 | Serotonin reuptake inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-04-07 | — | — | US | disclosed |
| EP-2627630-B1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE BIOPHARMA R & D IP LLC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140243536-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8729119-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-20130253013-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-8471040-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253013-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | TACR1 52/4885GPR119 628/4885MMP13 3853/4885 |
| US-20120088799-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | TACR1 52/4885GPR119 628/4885MMP13 3853/4885 |
| US-20140243536-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | TACR1 52/4885GPR119 628/4885MMP13 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.